Inozyme recently featured new clinical insights and hosted an educational symposium at the Joint Congress of the European ...

On April 23, 2025, the Company announced that three abstracts on Versamune® HPV (PDS0101) were selected for presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, to be ...

QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial results, the patient is expected to continue to be treated with QRX003 ...

MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ended March 31, 2025. The Company ...

H.C. Wainwright 6th Annual Neuro Perspectives Conference When: Tuesday, June 17 th, 2025 at 7:00 pm ET. A webcast is available to clients of the firm at https://hcwevents.com/.

BOSTON and LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported financial results and business highlights for ...

Lurie Children's Hospital of Chicago, a top-ranked hospital, is ready to evaluate patients for ZEVASKYN treatment - - Abeona Assist™ comprehensive patient services program in place to offer ...

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

Patient dosing has commenced, and the initial data readout is on track for the second half of 2025. For more information about the MIRACLE trial, visit clinicaltrials.gov and reference identifier ...

WARMINSTER, Pa., May 14, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, ...

As of March 31, 2025, LAVA had cash, cash equivalents, and short-term investments of $66.6 million, compared to cash, cash equivalents, and short-term investments of $76.6 million as of December 31, ...